It has been reported that MRP4 is expressed in blast cells of patients with AML and higher levels of this protein were detected in the less differentiated FAB subtypes M0 and M1; however, its expression has no influence on treatment outcome using AraC [9,10]. This evidence concerns the gene ABCC4 and acute myeloid leukemia.